Table 4.
Multivariate Cox proportional hazard model analysis of PFS and OS
| Variable | Progression-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
| Histology | ||||||
| ADC vs non-ADC | 1.154 | 0.637-2.622 | 0.255 | 1.118 | 0.563-2.527 | 0.248 |
| Performance status | ||||||
| 0-1 vs 2-3 | 1.845 | 1.052-2.995 | 0.114 | 2.532 | 1.219-4.325 | 0.013 |
| Disease stage | ||||||
| IIIB vs IV | 0.875 | 0.317-2.152 | 0.416 | 1.272 | 0.428-2.257 | 0.167 |
| EGFR status | ||||||
| Wild-type vs mutation | 2.726 | 1.415-4.655 | 0.011 | 2.615 | 1.338-4.524 | 0.014 |
| MUC1 mRNA at B0 | ||||||
| Positivity vs negativity | 2.359 | 1.155-4.326 | 0.018 | 2.494 | 1.536-4.721 | 0.015 |
| MUC1 mRNA at B4w | ||||||
| Positivity vs negativity | 2.855 | 1.512-4.779 | 0.007 | 2.842 | 1.975-5.013 | 0.009 |
| VEGF mRNA at B0 | ||||||
| Positivity vs negativity | 2.453 | 1.415-4.592 | 0.013 | 2.577 | 1.482-4.683 | 0.011 |
| VEGF mRNA at B4w | ||||||
| Positivity vs negativity | 3.012 | 2.103-5.148 | 0.004 | 2.910 | 1.971-5.106 | 0.006 |
ADC, adenocarcinoma.